InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,640.80
(
0.00%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.24
(
0.35%
)
Bitcoin
63,023.65
(
-0.04%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

LUMA14

Send PM Follow Ignore
Followers 8
Posts 508
Boards Moderated 0
Alias Born 07/04/2014

LUMA14

Re: None

Monday, 01/02/2017 7:30:35 AM

Monday, January 02, 2017 7:30:35 AM

Post# of 80490
TOPIC: ponatinib dose for pediatric patients

link to forum

...
Meinolf is right about no data in pediatrics. Phase 1 in pediatric population has not been done yet. There is only one case report in the literature about pediatric experience (Pediatr Blood Cancer. 2015 Nov;62(11):2050-1). They used 45 mg daily for an adolescent >70kg but reduced it to 15 mg for a concern of side effects.

We have used it for a 9 yo with Ph+ ALL and T315I mutation. This weight is about 30 kg and 1 m2 BSA. The patient received 15 mg daily and had a great response. I also hear from my US colleagues about their experience with children.

Nobuko Hijiya
...

If there is need doc´s will try Ponatinib.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up